

Special Issue

Advances in Esophageal Cancer

Message from the Guest Editor

Esophageal cancer is a disease with significant unmet clinical needs. Challenges in early diagnosis and ineffective systemic and local therapies contribute to why five-year survival is just 15%. Despite treatment with a potentially curative intent, nearly 40% of patients who achieve a complete pathological response recur within two years of completing treatment. Recurrent disease can present insidiously, and subsequent survival despite systemic and local therapy is often poor. Detecting recurrent esophageal cancer remains a challenge. Although significant research has been undertaken on the role of serum biomarkers including circulating tumor DNA in disease surveillance and in monitoring response to therapy, there is a lack of assays with sensitivity and specificity adequate for use in the current mainstream practice. Early detection of recurrence may enable patients to undergo targeted therapy, thereby improving long-term survival. This Special Issue focuses on the latest developments in monitoring efficacy of treatment, disease surveillance, and early detection of recurrence to help improve long-term survival.

Guest Editor

Dr. Sacheen Kumar
Department of Upper GI Surgery, Royal Marsden Hospital, London, UK

Deadline for manuscript submissions

closed (15 February 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/216220

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)